BioCentury | Oct 28, 2020
Product Development

Angelman trial pause for antisense oligo comes with efficacy data that lift Ultragenyx shares

GeneTx and Ultragenyx will look to adjust dosing and administration in their Phase I/II trial of GTX-102 to treat Angelman syndrome after patients experienced a serious adverse event thought...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Islet-like organoids expressing PD-L1 for diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Pancreatic islet-like organoids overexpressing PD-L1 and derived from human induced pluripotent stem cells (iPS cells) could be used to treat Type I diabetes. The organoids were generated by engineering human...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Feb 3, 2020
Product Development

GSK to provide adjuvant to boost effectiveness, stretch supplies of 2019-nCoV vaccines

GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday. AS03 has been used in GSK’s H1N1 and...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BioCentury | Oct 25, 2019
Company News

HIV sales prop up Gilead’s 3Q as Yescarta misses estimates

Gilead leaned on its HIV franchise to meet the Street’s expectations on its 3Q19 results, as HCV sales continued to fall and the company’s high-profile cell therapy Yescarta missed revenue expectations. Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

Chronic and genetic diseases company Reata Pharmaceuticals Inc. (NASDAQ:RETA) hired Manmeet Soni as CFO and EVP, succeeding Jason Wilson, who will become EVP of operations. Soni was CFO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Scholar Rock...
BioCentury | Aug 23, 2019
Politics & Policy

Coalition forms to push changes in antimicrobial payment system

To ensure that companies are incentivized to develop new antibiotics, a coalition of industry leaders has launched Working to Fight AMR to raise public awareness of antimicrobial resistance and encourage grassroots action to push forward...
BioCentury | Aug 14, 2019
Company News

Patient access, antisense oligo key to Angelman deal for Ultragenyx

Ultragenyx's partnership and option deal with Angelman syndrome company GeneTX delivers two components key to success in the rare disease: a candidate that targets the root cause of the disease, and a direct link to...
Items per page:
1 - 10 of 383
BioCentury | Oct 28, 2020
Product Development

Angelman trial pause for antisense oligo comes with efficacy data that lift Ultragenyx shares

GeneTx and Ultragenyx will look to adjust dosing and administration in their Phase I/II trial of GTX-102 to treat Angelman syndrome after patients experienced a serious adverse event thought...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Islet-like organoids expressing PD-L1 for diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Pancreatic islet-like organoids overexpressing PD-L1 and derived from human induced pluripotent stem cells (iPS cells) could be used to treat Type I diabetes. The organoids were generated by engineering human...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Feb 3, 2020
Product Development

GSK to provide adjuvant to boost effectiveness, stretch supplies of 2019-nCoV vaccines

GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday. AS03 has been used in GSK’s H1N1 and...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BioCentury | Oct 25, 2019
Company News

HIV sales prop up Gilead’s 3Q as Yescarta misses estimates

Gilead leaned on its HIV franchise to meet the Street’s expectations on its 3Q19 results, as HCV sales continued to fall and the company’s high-profile cell therapy Yescarta missed revenue expectations. Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

Chronic and genetic diseases company Reata Pharmaceuticals Inc. (NASDAQ:RETA) hired Manmeet Soni as CFO and EVP, succeeding Jason Wilson, who will become EVP of operations. Soni was CFO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Scholar Rock...
BioCentury | Aug 23, 2019
Politics & Policy

Coalition forms to push changes in antimicrobial payment system

To ensure that companies are incentivized to develop new antibiotics, a coalition of industry leaders has launched Working to Fight AMR to raise public awareness of antimicrobial resistance and encourage grassroots action to push forward...
BioCentury | Aug 14, 2019
Company News

Patient access, antisense oligo key to Angelman deal for Ultragenyx

Ultragenyx's partnership and option deal with Angelman syndrome company GeneTX delivers two components key to success in the rare disease: a candidate that targets the root cause of the disease, and a direct link to...
Items per page:
1 - 10 of 383